Streptomyces-Derived Nano-Doxorubicin: Clinical Status and Patents Granted
January 2024
in “
Scripta Medica
”
Studysummary This review highlights the potential of nanoparticle delivery systems to mitigate doxorubicin's adverse effects and enhance its effectiveness, while discussing the integration of nanotechnology with Streptomyces-derived compounds to potentially advance future cancer therapies.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer